Imaging and Laboratory Biomarkers in Cardiovascular Disease

Author(s): Maria Grazia Andreassi, Amalia Gastaldelli, Aldo Clerico, Piero A. Salvadori, Rosa Sicari, Eugenio Picano

Journal Name: Current Pharmaceutical Design

Volume 15 , Issue 10 , 2009

Become EABM
Become Reviewer
Call for Editor


Imaging and laboratory biomarkers are an essential support to modern practice of medicine, allowing a better identification, severity titration, staging and follow-up of atherosclerosis and heart failure disease. This review provides an overview of imaging, biochemical and genetic biomarkers used in clinical practice and for research purposes in order to evaluate the 4 different aspect of patient vulnerability to cardiovascular disease: arterial; blood; myocardial; metabolic vulnerability. Yet, no single perfect biomarker exists and there is wide room for optimization and integration between clinical evaluation and biomarker evaluation. In general, a targeted approach tailored on the individual patient should be preferred to a carpet diagnostic bombing, which will lead to an exorbitant multiplier of costs, risks and inappropriate testing.

Keywords: Atherosclerosis, biomarkers, cost, risk

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2009
Page: [1131 - 1141]
Pages: 11
DOI: 10.2174/138161209787846937
Price: $65

Article Metrics

PDF: 8